Alevca Ocular licenses technologies from Case Western Reserve to develop new ophthalmological drugs

By Jesse Schwartz
Published: January 10th, 2018

Early-stage drug company Alevca Ocular has licensed four technologies from Case Western Reserve University that they hope will lead to new ophthalmological treatments.

“Our initial push will be on drugs targeting inflammation [resulting] from cataract, LASIK and other eye surgeries, as well as from microbial causes,” says Chris Magill, CEO of Alevca.

The company licensed the technologies from Case Western Reserve’s Technology Transfer Office. The office has been working with inventor Eric Pearlman, a former professor in the university’s Department of Ophthalmology and Visual Sciences, to guide him through development and legal protections to help commercialize his innovations. Each of the licensed technologies is aimed at treating eye infection or irritation.

“I have been working with Dr. Pearlman for nearly a decade,” says Michael Haag, the TTO’s director of technology management. “I am gratified that his technology has the opportunity to benefit patients, and I am excited that Alevca, along with Dr. Pearlman himself, is primed to take this technology into the clinic.”

Alevca is preparing to complete financial and regulatory steps to accelerate the technology to clinical trials, and is seeking Series A funding.

“The Case Western Reserve licenses are essential components of Alevca’s development plan, and we appreciate the support the university’s Tech Transfer Office has provided and continues to provide as we grow our organization,” says Magill. “We aim to partner with big pharma to help accelerate programs and bring the drugs to market.”

Source: The Daily

No Comments so far↓
There are no comments yet...Kick things off by filling out the form below.

Leave a Comment